Oryzon Bolsters BPD Patent Portfolio with US Allowance

Event summary

  • Oryzon Genomics received a Notice of Allowance from the USPTO for a patent application covering the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder (BPD).
  • The patent, expected to be granted by 2040, complements Oryzon’s existing patent portfolio focused on aggression in BPD.
  • Corresponding patents have been granted or allowed in Australia, Europe, Japan, Mexico, Russia, Singapore, and South Africa.
  • ORYZON’s LSD1 inhibitor, vafidemstat, is advancing as a Phase III-ready asset for agitation/aggression in BPD.

The big picture

Oryzon’s strengthened patent position for vafidemstat represents a significant step in the development of novel treatments for BPD, a condition with limited therapeutic options. The company’s focus on epigenetics and CNS disorders positions it within a growing market segment, but success hinges on navigating the complexities of clinical trials and intellectual property protection. The Phase III trial for BPD will be a key inflection point for the company's valuation.

What we're watching

Commercialization
The success of Oryzon’s Phase III trial for BPD agitation/aggression will be critical in determining the commercial viability of vafidemstat and its ability to penetrate a market with significant unmet need.
Patent Defense
Given the value of the patent portfolio, Oryzon will likely face challenges from competitors seeking to develop similar LSD1 inhibitors, requiring ongoing vigilance and potential legal defense.
Pipeline Expansion
The company’s progress in expanding the application of vafidemstat to other CNS disorders, particularly those with genetic components, will influence its long-term growth trajectory and potential for precision medicine breakthroughs.

Related topics

Clinical Trial